130636-43-0

Usage

Uses

Used in Cardiology:
Nifekalant is used as an antiarrhythmic agent for the treatment of arrhythmias, particularly ventricular tachycardia and ventricular fibrillation. Its selective potassium ion channel blocking action and minimal adverse effects on hemodynamics make it a preferred choice in this application.
Used in Emergency Medicine:
Nifekalant is used as a rapid-acting antiarrhythmic agent for the management of life-threatening arrhythmias in emergency settings. Its rapid onset of action and excellent efficacy are crucial in these situations.
Used in Pharmaceutical Development:
Nifekalant is used as a reference compound in the development of new antiarrhythmic drugs, given its effectiveness and relatively low side effects profile. Researchers may study its mechanism of action to design safer and more effective medications for arrhythmia treatment.

InChI:InChI=1/C19H27N5O5.ClH/c1-21-17(14-18(26)22(2)19(21)27)20-9-11-23(12-13-25)10-3-4-15-5-7-16(8-6-15)24(28)29;/h5-8,14,20,25H,3-4,9-13H2,1-2H3;1H

Upstream product

• 6972-27-6 1,3-Dimethyl-6-chlorouracil 
• 20716-25-0 3-(4-nitrophenyl)-1-propanol 
• 5770-44-5 6-(2-hydroxyethylamino)-1,3-dimethylpyrimidine-2,4(1H,3H)-dion 
• 130636-37-2 (3-(4-nitrophenyl)propyl)-4-methylbenzene-1-sulfonate 
• 100-87-8 Benzylsulfonic acid 
• 130634-04-7 1,3-dimethyl-6-[2-(p-toluenesulfonyloxy)ethylamino)-2,4(1H,3H)-pyrimidinedione 
• 6642-31-5 6-Amino-1,3-dimethylbarbituric acid 
• 130634-09-2 N-(2-hydroxyethyl)-N-[3-(4-nitrophenyl)propyl]amine 

Downstream Products

• 130656-51-8 Shinbit 

Relevant academic research and scientific papers

A method for preparing high-purity hydrochloric acid Nepal non-Kalland

The invention discloses a preparation method of nifekalant hydrochloride. The preparation method comprises the following steps of: performing aminolysis on 6-imino-1,3-dimethyluracil to obtain 1,3-dimethyl-6-(2-ethoxy)aminouracil; esterfying 1,3-dimethyl-

Pyrimidinedione derivatives and antiarrhythmic agents containing same

Pyrimidinedione derivatives of the formula: STR1 wherein R1 and R2 is so linked with each other as to make an alkylene chain and thus form a heterocyclic structure, A, R3, R4, X1, X2 and X3 are substituents, respectively, and n is 2 or 3 have a basic backbone in which a phenyl group part and a pyrimidinedione part are linked by a structure comprising an alkyl chain and a heterocyclic ring having two nitrogen atoms. These compounds are useful for a medical treatment of cardiac arrhythmias.

Synthesis and pharmacological studies of N-substituted 6-[(2- aminoethyl)amino]-1,3-dimethyl-2,4(1H,3H)-pyrimidinediones, novel class III antiarrhythmic agents

A series of 6-[(2-aminoethyl)amino]-1,3-dimethyl-2,4(1H,3H)- pyrimidinedione derivatives were synthesized and studied for their class III electrophysiological activity and class II (β-blocking) effects in in vitro and in vivo models. Structure-activity re

Pyrimidinedione compounds, method of producing the same and antiarrythmic agents containing the same

A pyrimidinedione derivative compound has a basic backbone in which a phenyl group part and a pyrimidinedione part are linked by a structure comprising an alkyl chain containing at least two nitrogen atoms. The pyrimidinedione derivative is useful for a medical treatment of cardiac arrhythmias.